Introduction The prevalence of hepatitis B is higher in populations at risk, such as people living on the street. This population is more vulnerable to several diseases, such as hepatitis B, which can be prevented by adhering to the three-dose schedule of hepatitis B vaccine. The main goal was to investigate the vaccination situation against hepatitis B in this kind of population. Methods Cross-sectional study with quantitative approach. The research was developed at the Specialised Reference Centre for Homeless People (POP Centre). Participants were recruited through the Snowball Technique. The data were collected through the application of a form, from September to December 2016. This study was submitted and approved by the Research Ethics Committee of the Federal University of Piauí with the number of report 1,755,893. Results Of the 58 participants, the majority, 49 (84.5%) were males. The age ranged from 21 to over 50 years old. Regarding sexual behaviour, 7 (12.1%) participants reported feeling same-sex attraction. Only 3 (5.2%) reported having a monogamous partner, and among these, 2 (3.4%) reported not using condoms with the aforementioned partner. Only 11 (19.0%) participants had a vaccine card. Of the total, 35 (60.3%) did not know how to report their vaccination status. Of the doses of hepatitis B vaccine given previously, 3 (5.2%) reported having taken two doses of vaccine. The remainder, 15 (35.9%), had not taken any dose of the vaccine. Only 3 (5.2%) reported having completed the vaccination schedule. Conclusion Considering the low adherence to the three doses of vaccine against Hepatitis B, it is important to invest in the continuous supply of immunobiological and to expand orientation strategies regarding the importance of the complete vaccination scheme for this population. Introduction The elimination target for congenital syphilis (CS) is <50 cases per 1 00 000 live births. We describe trends of laboratory data for possible early CS across South Africa (SA) and estimate its incidence in infants over a six year period. Methods We conducted a cross-sectional analysis of laboratory data collected through the National Health Laboratory Service (NHLS) Corporate Data Warehouse (CDW) from 2010 to 2015. The NHLS CDW is a central repository of all laboratory tests performed in all public sector clinical laboratories in South Africa. We defined possible early CS as a positive serum Rapid Plasma Reagen (RPR) result in a child <2 years. Syphilis seropositivity rate was calculated as the number <2 years with a positive RPR test result divided by the total number <2 years tested during this time. Children with multiple RPR tests were counted once during this period. Incidence rate was calculated as the number of infants<1 year who had positive RPR results in a given year divided by the total number of livebirths for that year.
LB3.257 ESTIMATING PROGRESS TOWARDS ELIMINATION
Results Of 84 341<2 years tested during 2010-2015 (92.3% <1 year, 40 .7% male), 6357 (7.5%) tested positive. The number of children tested per year ranged from 23 555 in Gauteng Province to 1555 in the Northern Cape. RPR seropositivity in <2 years increased from 6% in 2010 to 9% in 2015 (p-value<0.001). Estimated national annual CS incidence rates in infants increased from 99/100,000 livebirths in 2010 to 119/100,000 livebirths in 2015. Largest increases in incidence rates were KwaZulu-Natal (44-115/100,000 livebirths), Limpopo (10-25/100,000 livebirths), and Mpumalanga (26-67/100,000 livebirths), while declines were observed in Eastern Cape (278-178/100,000 livebirths), Northern Cape (168-66/100,000 livebirths) and Free State (84-51/100,000 livebirths). Conclusion Though limited to laboratory results, the analysis shows high incidence possible CS. SA may need to intensify elimination efforts to reach the WHO target. Further clinical and maternal treatment information is needed in order to confirm incidence rates of early CS. Introduction STI self-sampling accessed via the internet (e-STI testing) is recommended to expand access to services. There is limited evidence on its effectiveness. This is the first RCT to evaluate an e-STI testing service for chlamydia, gonorrhoea, HIV and syphilis. Methods Single-blind RCT with allocation concealment.
Eligibility: aged 16-30, resident in 2 boroughs of London, having at least one sexual partner in the last 12 months, willing to take an STI test.
Participants were randomly allocated to (1) an e-STI testing service or (2) to a website with signposting to local sexual health clinics.
Primary outcomes were: 1) diagnosis of any STI 2) completion of any STI test All analyses were intention-to-treat. We used multivariate imputation using chained equations (MICE) for the primary analyses. We explored heterogeneity by age, gender, ethnicity, deprivation, number of sexual partners in the last 12 months, and sexuality. Results 2072 participants were randomised. The response rate was 84%. At 6 weeks, 50.0% of the intervention group completed an STI test compared to 26.6% in the control group (RR 1.87, 95% confidence interval 1.63 to 2.15, p<0.0001). 2.8% of the intervention v 1.4% in the control were diagnosed with an STI (RR 2.10, 95% confidence interval 0.94 to 4.70, p=0.079). The effect on cases treated was 1.1% in the intervention v 0.7% in the control (RR 1.72, 95% confidence interval 0.71 to 4.16, p=0.231).
No heterogeneity was observed in the pre-specified sub group analyses.
Time-to-test was lower in the intervention arm compared to the control arm (28.8 days vs 36.5 days; p<0.0001). No differences were observed for time-to-treatment (83.2 days vs 83.5 days; p=0.51).
Data cleaning and data collection were still underway late 2016. Conclusion e-STI testing increased testing uptake and may yield a small increase in STI diagnoses. Service innovations may be needed so that gains in testing and diagnoses translate into similar gains in cases treated. e-STI testing could be a valuable option in high prevalence contexts where expanding access is priority.
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Introduction Mycoplasma genitalium (MG) is a common cause of urethritis in men. In the U.S., CDC recommends treatment for MG with azithromycin or moxifloxacin, but treatment success is threatened by increasing resistance to both therapies. Rectal MG infection has been described among MSM, but little is known about rectal MG prevalence and frequency of antibiotic-resistant MG in HIV-infected MSM. Methods We retrospectively evaluated the prevalence of MG infection and antibiotic-resistant MG in 158 HIV-infected MSM who self-collected rectal and urine samples for a study at an HIV clinic in Birmingham, Alabama in 2014-2016. Eligibility criteria included receptive anal intercourse in the past 30 days and no recent antibiotic exposure (except trimethoprim-sulfamethoxazole). A real-time PCR assay was used to detect MG and macrolide resistance by targeting the 23S rRNA gene. Nested PCRs were used to detect mutations in quinolone resistant determination regions in gyrA, gyrB, parC and parE genes. Results MG infection was detected in 27 MSM (17.1%); 18 (11.4%) at the genital site and 9 (5.7%) at the rectal site. The bacterial load ranged from 2-32,700 genome copies/ml. Macrolide resistant MG was detected in 19 men (70.4%), featuring typical 23S rRNA mutations (A2071G or A2072G transitions). One subject with MG had novel gene mutations (G1972T and G2038T) with unknown function. Eight (29.6%) had fluoroquinolone-resistant MG harbouring parC mutations that cause changes in amino acid position 83 (S83I or S83R); 4 of them had an additional P62S mutation in parC and 1 had a F475S mutation in gyrB. Five men (18.5%) had MG with dual macrolide and fluoroquinolone resistance. The prevalence of resistance was similar at rectal and genital sites. Conclusion This is the first U.S. study to document a high frequency of macrolide and fluoroquinolone-resistant MG in HIV-infected MSM at rectal and genital sites. If these resistance mutations are associated with clinical treatment failure, more effective options to treat MG are needed. Introduction Men-who-have-sex-with-men (MSM) may modify sexual practices to reduce HIV and sexually transmitted infection (STI) risk. HIV pre-exposure prophylaxis (PrEP) may impact risk behaviour and STI acquisition. Methods We matched HIV-negative MSM attending New York City (NYC) sexual health clinics during 2011-2015 to the NYC HIV registry in 01/2017. We used visit-level data to assess trends in condom use during anal sex (consistent, inconsistent, no use; referent period=3 months), overall and by sexual positioning behaviour. We examined associations between condomless (inconsistent/no use) insertive, condomless receptive, and condomless versatile sex and incident HIV or STI (chlamydia/gonorrhoea/early syphilis). We used regression with generalised estimating equations (referent group=anal sex with condoms), controlling for demographics, partner number, and STI history. Results The proportion of visits with reported consistent condom use decreased from 2011-2015 (39% to 31%%, p<0 .001); inconsistent use increased (48% to 55%%), and no condom use was stable (13%-14%).There were significant declines in consistent condom use across all positioning categories. From all visits, MSM reported positioning as: 19% condomless insertive, 9% condomless receptive, 37% condomless versatile, 35% sex with condoms. For 25,216 STI testing visits that yielded 7438 diagnoses, all condomless-positioning categories were associated with incident STI; highest risk was with condomless insertive sex (aOR 1.8, 95% CI 1.6-1.9). For MSM tested for HIV at 9744 visits, condomless receptive (aOR 2.8; 95% CI 1.9-4.1) and condomless versatile sex (aOR 2.2; 95% CI 1.6-2.8) were associated with incident HIV. Black MSM (~25% of MSM) had the highest risk for STI and HIV (41% of 368 new HIV diagnoses). Conclusion We documented increases in condomless sex among a sentinel high risk group prior to and during the PrEP era. Insertive sex, perhaps perceived as a safer strategy, was associated with substantial STI risk when condoms were not consistently used. Assuring PrEP access for black MSM is critical.
LB3.261 TRENDS IN CONDOM USE AND SEXUAL POSITIONING AMONG MEN-WHO-HAVE-SEX-WITH-MEN IN THE ERA OF HIV PRE-EXPOSURE PROPHYLAXIS, AND RISK FOR DIAGNOSES OF INCIDENT HIV AND OTHER SEXUALLY TRANSMITTED INFECTIONS
Introduction Among children, the main postnatal HIV category of exposure is breastfeeding. When acute maternal infection occurs during lactation, the high maternal viral rate results in a higher risk of infant infection. There are few researches showing the impact of HIV infection on children of previously seronegative mothers, who acquire the HIV virus during breastfeeding. To elucidate the importance of this category of exposure, this study aims to evaluate HIV infection in infants assisted by a Paediatric Infectology Service in Brazil, emphasising the cases where vertical transmission occurred lately through breastfeeding. Methods Transversal, analytical and descriptive study, with quantitative and qualitative approach analysing HIV infected patients from 0 to 16 years old. Data was collected during 2016, from charts of children assisted between 2010 and 2015. After previous selection, breastfed children of mothers who had negative HIV testing during pregnancy and/or at birth, had charts analysed in detail.
Results From a total of 122 cases, 95% were mother-to-childtransmissions. Between these cases, 11 were considered possible/confirmed late postnatal transmission through breastfeeding. This group characterisation showed that at diagnosis, 72,7% presented significant and/or recurrent symptoms of HIV infection. In 45,4%, mother and children were diagnosed at the same time and 72,7% of mothers were sexually infected. Conclusion There was a significant prevalence of late postnatal transmission through breastfeeding in our sample. Differently from resource limited settings, most countries avoid breastfeeding by HIV infected mothers. Considering cases where women were infected only during lactation, our study highlights a gap in prevention of vertical transmission of HIV. The severity of infant symptoms, the moment of diagnosis and mother's category of exposure confirm the importance of preventive measures and scientific improvement to reduce postnatal HIV transmission.
